EUROAPI EUROAPI

X
[{"orgOrder":0,"company":"NYU Grossman School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antianxiety and Antidepressant Effects from a Single Dose of Psychedelic Drug Persist Years Later in Cancer Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"NYU Grossman School of Medicine"},{"orgOrder":0,"company":"NineteenGale Therapeutics","sponsor":"Cyclica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroTheryX Partners with Cyclica to Launch NineteenGale Therapeutics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"NineteenGale Therapeutics"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Receives Issue Notification for Patent Covering AD04 for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Adial Pharmaceuticals"},{"orgOrder":0,"company":"CB Therapeutics","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CB Therapeutics Enters into Collaboration Agreement with Cleveland Clinic for the Manufacture of Psilocybin","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"CB Therapeutics"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"VistaGen Therapeutics"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"CaaMTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CaaMTech Collaborates With National Institutes of Health to Research Psychedelics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"National Institute on Drug Abuse"},{"orgOrder":0,"company":"University Hospital Basel","sponsor":"Mind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"University Hospital Basel"},{"orgOrder":0,"company":"Katana Pharmaceuticals","sponsor":"March of Dimes","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Katana Pharmaceuticals Gets $1.05 M Grant to Support the Development of a Novel Non-Opioid Treatment for Neonatal Abstinence Syndrome","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Katana Pharmaceuticals"},{"orgOrder":0,"company":"Delos Psyche Research Group","sponsor":"New Wave Holdings Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"New Wave Holdings Corp Provides Funding for LSD Research Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Delos Psyche Research Group"},{"orgOrder":0,"company":"NeuroPharma","sponsor":"Mydecine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mydecine Innovations Group to Acquire NeuroPharm Inc.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"NeuroPharma"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Cybin Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cybin Corp. and IntelGenx Corp. Enter Into Feasibility Agreement for Fast-Acting, Orally-Dissolving Psilocybin Film","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"IntelGenx"},{"orgOrder":0,"company":"Kures","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ATAI Life Sciences Takes on Opioid Crisis by Acquiring Kures to Develop Novel Therapeutics for Opioid Abuse","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Kures"},{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OWP Pharmaceuticals Announces Patent Application for the First-Ever Powder for Oral Liquid Formulation of Duloxetine Hydrochloride for Major Depressive and Generalized Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"OWP Pharmaceuticals"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Announces Patent Granted in the U.S. for Novel Analogs of Cytisinicline for Use in CNS and Addiction Indications","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Achieve Life Sciences"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Reports Synergistic Suppression of Suicide-Associated Neuroinflammatory Pathway by QuadraMune\u2122 and Minocycline","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Therapeutic Solutions"},{"orgOrder":0,"company":"Curia","sponsor":"Tryp Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tryp Therapeutics Partners with Curia to Manufacture a Proprietary Psilocybin-based Drug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Curia"},{"orgOrder":0,"company":"CannaGlobal Wellness","sponsor":"Sansero Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CannaGlobal, Sansero Life Sciences and Rise Wellness Complete Merger, Announce Formation of CannaGlobal Wellness","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"CannaGlobal Wellness"},{"orgOrder":0,"company":"Proniras","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$12.3 million","upfrontCash":"Undisclosed","newsHeadline":"Proniras Corporation Announces National Institute on Drug Abuse (NIDA) Grant Award to Pursue Treatment for Opioid Withdrawal","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Proniras"},{"orgOrder":0,"company":"Mydecine","sponsor":"Canaccord Genuity Corp.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mydecine Innovations Group Files Preliminary Prospectus in Connection with Bought Deal Offering of Units","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Mydecine"},{"orgOrder":0,"company":"University of Maryland","sponsor":"Mydecine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"University of Maryland"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"MYND Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MYND Life Sciences Inc. Announces Collaborative Research Agreement with the University of British Columbia on Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"University of British Columbia"},{"orgOrder":0,"company":"PPD","sponsor":"US Army","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PPD Awarded US Army Study to Help Develop Post-Traumatic Stress Disorder Drugs","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"PPD"},{"orgOrder":0,"company":"Imperial Collage London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magic Mushroom Compound Performs as Well as Antidepressant in Small Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Imperial Collage London"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Braxia Scientific Awarded Government of Canada Funding to Complete First of its Kind Ketamine Clinical Trial for Bipolar Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Braxia Scientific"},{"orgOrder":0,"company":"Allied Corp","sponsor":"HAVN Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allied Corp Signs Psilocybin Manufacturing Agreement To Produce Psilonex\u2122 RX","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Allied Corp"},{"orgOrder":0,"company":"Mydecine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Mydecine"},{"orgOrder":0,"company":"Mydecine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mydecine Expands Portfolio Novel Molecules Filing New Patent MDMALike Compound","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Mydecine"},{"orgOrder":0,"company":"Shaare Zedek Scientific Ltd.","sponsor":"Greater Cannabis Company","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GCANRx Signs Licensing Agreement with Shaare Zedek Scientific for Innovative Neuropsychiatric Cannabinoid Therapy","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Shaare Zedek Scientific Ltd."},{"orgOrder":0,"company":"Mycrodose Therapeutics","sponsor":"HAVN Life","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HAVN Life Announces Supply and Distribution MOU with Mycrodose Therapeutics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Mycrodose Therapeutics"},{"orgOrder":0,"company":"Psyence","sponsor":"Pure Extracts Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"A Joint Venture Sealed between Psyence Group and Pure Extracts: Psychedelic Medicinal Mushroom Extracts in Development","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Psyence"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON to Present New Clinical Data and Corporate Updates at International Conferences in September and October","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Oryzon Genomics"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braxia Scientific Reports Encouraging Results of Ketamine Study Showing Significant Reduction in Depressive Symptoms and Suicidality with Ketamine as a Solo Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Braxia Scientific"},{"orgOrder":0,"company":"Delic Corp","sponsor":"Ketamine Wellness Centers","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ketamine Wellness Centers Partners with Veterans Affairs (VA) Community Care Network to Provide Free Ketamine Treatments to Veterans","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Delic Corp"},{"orgOrder":0,"company":"Beijing Wonner Biotech","sponsor":"Shineco","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Shineco, Inc. Intends to Acquire Biotechnology Company to Jointly Develop Rapid-acting Antidepressant Natural Innovative Medicine","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Beijing Wonner Biotech"},{"orgOrder":0,"company":"Mydecine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Mydecine"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"EF Hutton","pharmaFlowCategory":"D","amount":"$30.4 million","upfrontCash":"Undisclosed","newsHeadline":"Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Pasithea Therapeutics"},{"orgOrder":0,"company":"MicroDoz Therapy Inc.","sponsor":"Love Pharma","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Love Pharma\u2019s Acquisition Will Offer Exclusive Partnership and License with World Renowned University to Conduct Landmark Psilocybin Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"MicroDoz Therapy Inc."},{"orgOrder":0,"company":"Monash University","sponsor":"Incannex Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"World-First Psilocybin Clinical Trial in The Treatment of Generalised Anxiety Disorder Receives Ethics Approval","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Monash University"},{"orgOrder":0,"company":"Mydecine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Mydecine"},{"orgOrder":0,"company":"MD Infusions","sponsor":"Front Door Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Front Door Health Launches Joint Venture with MD Infusions to Deliver Novel In-home Ketamine Treatment for Addiction and Mental Health Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"MD Infusions"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Hebrew University of Jerusalem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Establishes Third R&D Partnership With the Hebrew University","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Clearmind Medicine"},{"orgOrder":0,"company":"CB Therapeutics","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CB Therapeutics and atai Life Sciences Launch TryptageniX to Sustainably Supply and Develop Clinically Relevant Compounds to Tackle the Growing Mental Health Crisis","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"CB Therapeutics"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braxia Scientific Provides Update on Large Proprietary Dataset Expected to Support Pharmaceutical and Industry Clinical Trials for Ketamine and Psilocybin Drug Development","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Braxia Scientific"},{"orgOrder":0,"company":"Awakened Biosciences","sponsor":"Core One Labs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Core One Labs Completes Strategic Acquisition of Awakened Biosciences and its Game-Changing Provisional Patents","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Awakened Biosciences"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"OnDosis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"New Agreement Expands Collaboration Between Ondosis and Tiefenbacher Group","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Tiefenbacher Group"},{"orgOrder":0,"company":"Psyence","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Psyence Taps Another Pharma Exec to Drive its Clinical Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Psyence"},{"orgOrder":0,"company":"Open Book Extracts","sponsor":"Biopharmaceutical Research Company","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Open Book Extracts & Biopharmaceutical Research Company Establish Research & Development Collaboration","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Open Book Extracts"},{"orgOrder":0,"company":"Optimi Health","sponsor":"SABI Mind","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Optimi Health"},{"orgOrder":0,"company":"Unlimited Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unlimited Sciences Announces Groundbreaking New Study to Observe Ayahuasca\u2019s Effects on Trauma","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Unlimited Sciences"},{"orgOrder":0,"company":"Optimi Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Optimi Health Unveils Canada\u2019s First Natural Therapeutic Psilocybin Product For Approved Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Optimi Health"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Societal CDMO Announces Signing of Multiple Agreements With New and Existing Customers","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Societal CDMO"},{"orgOrder":0,"company":"Naltrexone Therapeutics","sponsor":"Love Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Love Pharma Signs Letter of Intent to Acquire Naltrexone Therapeutics Inc.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Naltrexone Therapeutics"},{"orgOrder":0,"company":"Psyence","sponsor":"Brandon Kerzner","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"Undisclosed","newsHeadline":"Psyence Group Announces Closing of Second Tranche of Private Placement and Appointment of Strategic Advisor","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Psyence"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"SciSparc"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"FSD Pharma"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"SciSparc"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Adamis Pharmaceuticals"},{"orgOrder":0,"company":"Fertin Pharma AS","sponsor":"Philip Morris International","pharmaFlowCategory":"D","amount":"$820.0 million","upfrontCash":"Undisclosed","newsHeadline":"Philip Morris International Announces Closing of Fertin Pharma Acquisition; Advances PMI\u2019s Goal of Becoming a Majority Smoke-Free Business by 2025 and Creates Growth Opportunities Beyond Nicotine","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Fertin Pharma AS"},{"orgOrder":0,"company":"Fertin Pharma AS","sponsor":"Philip Morris International","pharmaFlowCategory":"D","amount":"$820.0 million","upfrontCash":"Undisclosed","newsHeadline":"Philip Morris International Announces Agreement to Acquire Fertin Pharma","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Fertin Pharma AS"},{"orgOrder":0,"company":"Magdalena Biosciences","sponsor":"One Small Planet","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Magdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Receives Second Tranche of Funding from One Small Planet","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Magdalena Biosciences"}]

Find Novel Psychiatry/Psychology Drugs in Clinical Development

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            The partnership aims to develop and commercialize products in the intersection between traditional drug-based medicine and digital therapeutics. Another novelty is to dispense the drugs as pellets instead of pills or capsules, making them easier to consume.

            Lead Product(s): Undisclosed

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: OnDosis

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Expanded Collaboration September 26, 2021

            Tiefenbacher Compnay Banner

            Cosmoprof India

            Not Confirmed

            envelop Contact Supplier

            Details:

            Curia will provide research, development and cGMP manufacturing of a proprietary psilocybin active pharmaceutical ingredient to support the clinical development of TRP-8802, TRP-8803 and TRP-8804 programs.

            Lead Product(s): Psilocybine

            Therapeutic Area: Psychiatry/Psychology Product Name: TRP-8802

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Tryp Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership August 13, 2020

            Curia CB

            Cosmoprof India

            Not Confirmed

            envelop Contact Supplier

            Details:

            The net proceeds will be used to develop novel, natural prescription medicines derived from plants for mental health indications such as depression, anxiety, attention-deficit/hyperactivity disorder (ADHD) and other possible neuropsychiatric conditions initially in adults.

            Lead Product(s): Undisclosed

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: One Small Planet

            Deal Size: $1.0 million Upfront Cash: Undisclosed

            Deal Type: Financing October 30, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The net proceeds from the funding will be used to support the development of a novel bifunctional small molecule for the treatment of Alcohol Use Disorder (AUD).

            Lead Product(s): Undisclosed

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding June 26, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration aims to strengthens IP portfolio with patent application in the U.S. For treatment of depression. The latest patent application refers to the protection of the unique combination of MEAI and SciSparc's Palmitoylethanolamide (PEA).

            Lead Product(s): Palmitoylethanolamide,5-Methoxy-2-Aminoindane

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Clearmind Medicine

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the collaboration, three provisional patent applications were filed by Clearmind. The patent applications refer to novel proprietary combinations of LSD, psilocybin, and DMT and SciSparc’s Palmitoylethanolamide, the active ingredient of its proprietary CannAmide™.

            Lead Product(s): Palmitoylethanolamide,5-Methoxy-2-Aminoindane

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Clearmind Medicine

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Substance misuse is one of the most pervasive challenges around the globe, keeping this it in mind, company has announced the launch of a new research and development program focused on unmet medical needs for alcohol misuse disorder.

            Lead Product(s): Undisclosed

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 14, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.

            Lead Product(s): Psilocybine

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Brandon Kerzner

            Deal Size: $2.1 million Upfront Cash: Undisclosed

            Deal Type: Private Placement December 14, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Naltrexone Therapeutics

            Contact Supplier
            • Deals
            Virtual Booth Virtual Booth
            Digital Content Digital Content

            Details:

            Naltrexone is an opioid antagonist, primarily used to manage alcohol and or opioid use disorder by reducing cravings and feelings of euphoria associated with substance abuse disorder.

            Lead Product(s): Naltrexone

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Love Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition October 11, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The new contracts are focused on a range of analytic method, tech transfer, formulation, manufacturing and packaging services designed to support ongoing clinical development programs, as well as planned commercial activities.

            Lead Product(s): Undisclosed

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 29, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY